Neuroendocrine aspects of the molecular chaperones ADNF and ADNP

Molecular Chaperones and Cell Signalling

Volumn , Issue , 2005, Pages 251-262

  Gozes, Illana ^a   Vulih, Inna ^a   Spivak Pohis, Irit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34147132180     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511546310.016     Document Type: Chapter

References (48)

1. Gozes I and Brenneman D E. VIP: molecular biology and neurobiological function. Mol Neurobiol 1989, 3: 201-236.
2. Gozes I, Fridkin M, Hill J M and Brenneman D E. Pharmaceutical VIP: prospects and problems. Cur Med Chem 1999, 6: 1019-1034.
3. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M and Brenneman D E. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 1996, 93: 427-432.
4. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M and Giladi E. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer’s disease. J Neurobiol 1997, 33: 329-342.
5. Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinraut S and Fridkin M. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc Natl Acad Sci USA 1999, 96: 4143-4148.
6. Brenneman D E and Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest 1996, 97: 2299-2307.
7. Brenneman D E, Hauser J, Neale E, Rubinraut S, Fridkin M, Davidson A and Gozes I. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Therap 1998, 285: 619-627.
8. Guo Q, Sebastian L, Sopher B, Miller M W, Glazner G W, Ware C B, Martin G M and Mattson M. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci USA 1999, 96: 4125-4130.
9. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman D E and Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999, 72: 1283-1293.
10. Glazner G W, Boland A, Dresse A E, Brenneman D E, Gozes I and Mattson M P. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death. J Neurochem 1999, 73: 2341-2347.
11. Glazner G W, Camandola S and Mattson M P. Nuclear factor-kappaB mediates the cell survival-promoting action of activity-dependent neurotrophic factor peptide-9. J Neurochem 2000, 75: 101-108.
12. White D M, Walker S, Brenneman D E and Gozes I. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Res 2000, 868: 31-38.
13. Zamostiano R, Pinhasov A, Bassan M, Perl O, Steingart R A, Atlas R, Brenneman D E and Gozes I. A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neurosci Lett 1999, 264: 9-12.
14. Gressens P, Marret S, Bodenant C, Schwendimann L and Evrard P. Activity- dependent neurotrophic factor-14 requires protein kinase C and mitogen-associated protein kinase kinase activation to protect the developing mouse brain against exci- totoxicity. J Mol Neurosci 1999, 13: 199-210.
15. Guo Z H and Mattson M P. Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb Cortex 2000, 10: 50-57.
16. Blondel O, Collin C, McCarran WJ, Zhu S, Zamostiano R, Gozes I, Brenneman D E and McKay R D. A glia-derived signal regulating neuronal differentiation. J Neurosci 2000, 20: 8012-8020.
17. Gozes I, Giladi E, Pinhasov A, Golian T, Romano J and Brenneman D E. Activity- dependent neurotrophic factor: comparison of intranasal and oral administration of femtomolar-acting L and D peptides to improve memory. Soc Neurosci Abstract 2000: 223.
18. Steingart R A, Solomon B, Brenneman D E, Fridkin M and Gozes I. VIP and peptides related to activity-dependent neurotrophic factorprotect PC12 cells against oxidative stress. J Mol Neurosci 2000, 15: 137-145.
19. Brenneman D E, Hauser J and Gozes I. Synergistic and non-chiral characteristics in dissociated cerebral cortical test cultures. Soc Neurosci Abstract 2000 223-224.
20. Gozes I, Davidson A, Gozes Y, Mascolo R, Barth R, Warren D, Hauser J and Brenneman D E. Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Brain Res Dev Brain Res 1997, 99: 167-175.
21. Gozes I and Brenneman D E. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 1996, 7: 235-244.
22. Hashimoto Y, Niikura T, Ito Y, Sudo H, Hata M, Arakawa E, Abe Y, Kita Y and Nishimoto I. Detailed characterization of neuroprotection by a rescue factor hu- manin against various Alzheimer’s disease-relevant insults. J Neurosci 2001, 21: 9235-9245.
23. Ramirez S H, Sanchez J F, Dimitri C A, Gelbard H A, Dewhurst S and Maggirwar S B. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor- kappaB (NF-kappaB)-dependent mechanism. J Neurochem 2001, 78: 874-889.
24. Zamostiano R, Pinhasov A, Gelber E, Steingart R A, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre H J, Mulley J C, Brenneman D E and Gozes I. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001, 276: 708-714.
25. Sigalov E, Fridkin M, Brenneman D E and Gozes I. VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. J Mol Neurosci 2000, 15: 147-154.
26. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman D E and Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson’s disease. Brain Res 2000, 854: 257-262.
27. Zemlyak I, Furman S, Brenneman D E and Gozes I. A novel peptide prevents death in enriched neuronal cultures. Reg Peptides 2000, 96: 39-43.
28. Gozes I and Brenneman D E. A new concept in the pharmacology of neuroprotection. J Mol Neurosci 2000, 14: 61-68.
29. Gozes I, Alcalay R, Giladi E, Pinhasov A, Furman S and Brenneman D E. NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci 2002, 19: 167-170.
30. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart R A, Brenneman D E, Eizenberg O, Trembolver V and Shohami E. A peptide derived from activity- dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther2001, 296: 57-63.
31. Romano J, Beni-Adani L, Nissenbaum O L, Brenneman D E, Shohami E and Gozes I. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. J Mol Neurosci 2002, 18: 37-45.
32. Spong C Y, Abebe D T, Gozes I, Brenneman D E and Hill J M. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Therap 2001, 297: 774-779.
33. Newton P E, Brenneman D E and Gozes I. 30-day intranasal toxicity studies of NAP in rats and dogs. J Mol Neurosci 2001, 16: 61.
34. Pelsman A, Fernanandez G, Gozes I, Brenneman D E and Busciglio J. Invitro degeneration of Down syndrome neurons is prevented by activity-dependent neurotrophic factor-derived peptides. Soc Neurosci Abstracts 1998, 24: 1044.
35. Leker R R, Teichner A, Grigoriadis N, Ovadia H, Brenneman D E, Fridkin M, Gi- ladi E, Romano J and Gozes I. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 2002, 33: 1085-1092.
36. Smith-Swintosky V L, Gozes I, Brenneman D E and Plata-Salaman C R. Activity dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. Soc Neurosci Abstracts 2000, 26: 843.
37. Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman D E and Spier A D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 2003, 20: 315-322.
38. Divinski I, Spier A D and Gozes I. NAP, a peptide derivative of the VIP-regulated gene ADNP, confers neuroprotection through microtubule dynamics. Reg Peptides 2003, 115: 42.
39. Ashur-Fabian O, Giladi E, Furman S, Steingart R A, Wollman Y, Fridkin M, Brenneman D E and Gozes I. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neurosci Lett 2001, 307: 167-170.
40. Steinhoff U, Zugel U, Wand-Wurttenberger A, Hengel H, Rosch R, Munk M E and Kaufmann SHE. Prevention of autoimmune lysis by T cells with specificity for a heat shock protein by antisense oligonucleotide treatment. Proc Natl Acad Sci USA 1994, 91: 5085-5088.
41. Birk O S, Douek D C, Elias D, Takacs K, Dewchand H, Gur S L, Walker M D, van der Zee R, Cohen I R and Altmann D M. A role of hsp60 in autoimmune diabetes: analysis in a transgenic model. Proc Natl Acad Sci USA 1996, 93: 1032-1037.
42. Kurek J B, Bennett TM, Bower JJ, Muldoon C M and Austin L. Leukaemia inhibitory factor (LIF) production in a mouse model of spinal trauma. Neurosci Lett 1998, 249: 1-4.
43. Bassan M, Zamostiano R, Giladi E, Davidson A, Wollman Y, Pitman J, Hauser J, Brenneman D E and Gozes I. The identification of secreted heat shock 60-like protein from rat glial cells and a human neuroblastoma cell line. Neurosci Lett 1998, 250: 37-40.
44. Hollander J M, Lin K M, Scott B T and Dillmann W H. Overexpression of PHGPx and HSP60/10 protects against ischemia/reoxygenation injury. Free Radic Biol Med 2003, 35: 742-751.
45. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig A M, Servoss S J, Brenneman D E and Gozes I. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 2003, 144: 83-90.
46. Zaltzman R, Beni S M, Giladi E, Pinhasov A, Steingart R A, Romano J, Shohami E and Gozes I. Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. Neuroreport 2003, 14: 481-484.
47. Alcalay R N, Giladi E, Pick C G and Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 2004, 361: 128-131.
48. Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman D E, Steingart R A, Giladi E and Gozes I. The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 2003, 24: 1413-1423.